|
|
|
Volumn 28, Issue SUPPL. 2, 2002, Pages 49-50
|
|
Conclusion - Benefit of selective factor inhibition
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
COUMARIN DERIVATIVE;
ENOXAPARIN;
FONDAPARINUX;
HEPARIN DERIVATIVE;
LOW MOLECULAR WEIGHT HEPARIN;
THROMBIN INHIBITOR;
ANTITHROMBIN III;
POLYSACCHARIDE;
THROMBIN;
BLEEDING TENDENCY;
CLINICAL FEATURE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG SAFETY;
HUMAN;
LUNG EMBOLISM;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
THROMBOSIS PREVENTION;
VEIN THROMBOSIS;
ARTICLE;
DRUG ANTAGONISM;
DRUG DESIGN;
ENZYME SPECIFICITY;
THROMBOEMBOLISM;
ANTITHROMBIN III;
CLINICAL TRIALS;
DRUG DESIGN;
HEPARIN, LOW-MOLECULAR-WEIGHT;
HUMANS;
POLYSACCHARIDES;
SUBSTRATE SPECIFICITY;
THROMBIN;
THROMBOEMBOLISM;
|
|
EID: 0036285277
PISSN: 00946176
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (2)
|
|
References (0)
|
